Who uses #cannabis in #rheumatic #diseases? Those who smoke, have higher pain, more anxiety, poor sleep are more likely to have used cannabis for their rheumatic disease. Half of the >2900 respondents have tried #cannabis. Use of #biologics reduced use. #980 @RheumNow @ACRheum https://t.co/DQDRQN40zR

Wouldn’t it be great to be able to predict which women with RA would improve during pregnancy, & which would worsen? We’d be able to adjust DMARDs accordingly. Gene expression signatures might tell us more - one key cluster here was 21x predictive. #ACR23 ABST2481 @RheumNow https://t.co/OiDV5sUiYC

#ACR23 Abstr# 2488 Phase 2 RCT #SLE showed more patients on ABBV-599 HD (elsubrutinib (BTK-i) + UPA (JAK-i)) and UPA monotherapy met primary & secondary endpoints vs PBO at WK48W. No major malignancy/VTE concerns. No added superiority by adding BTK-i vs UPA alone @RheumNow https://t.co/MUN2o75gEE

During "Rashes in Rheumatology talk at #ACR23, Dr. Katherine Shaw does not routinely use HCQ for DM skin manifestations. ⭐️Only ~10% of DM patients respond to monotherapy with HCQ but potential increased risk of hypersensitivity, especially in MDA5-DM ➡️Suspect that slight HCQ… https://t.co/aRmFmzuAum

HCQ and risk of retinopathy 👁️ DoD database HCQ 44000+ females & 10000+ males Risk retinopathy HR 1.5 Variations according to diagnosis SLE higher risk vs. RA, more so in males HR 2, females HR 1.7 No adjustment on HCQ dose @RheumNow #ACR23 ABST2452 https://t.co/TtTu6ixb45

@md_chawla @RheumNow https://t.co/PVxox5t8ZH

• https://twitter.com/MeralElRamahiMD/status/1724563138379428198/photo/1
• https://twitter.com/MeralElRamahiMD/status/1724563138379428198/photo/1
• https://twitter.com/MeralElRamahiMD/status/1724563138379428198/photo/1
• https://twitter.com/MeralElRamahiMD/status/1724563138379428198/photo/1

@md_chawla @RheumNow https://t.co/qSdT7by1Vh

• https://twitter.com/MeralElRamahiMD/status/1724563367753355299/photo/1
• https://twitter.com/MeralElRamahiMD/status/1724563367753355299/photo/1
• https://twitter.com/MeralElRamahiMD/status/1724563367753355299/photo/1

Erosive hand #OA may be more painful than treated #RA patients. The burden of OA is often not alked about, and this study highlights it! @RheumNow #ACR23 https://t.co/jLbvtMmgE0

#ACR23 Abstr# 2489 I can’t wait for Phase 3 RCT results as I have many #SLE patients with refractory cutaneous lupus. Post-hoc analyses of Phase 2 RCT of Deucravacitinib showed its efficacy (CLASI-50) over PBO across all CLE subtypes @RheumNow https://t.co/G7edkAU18J

And to continue B-SAFE Clinical risk score for HCQ retinopathy 👁️ 10 years 4000+ pts, 3% retinopathy over 5yrs Predictors of HCQ retinopathy -body weight -sex -age -eGFR -weight based dose mg/kg -higher cumulative dose Risk ranges 1% to >20% @RheumNow #ACR23 ABST2453 https://t.co/h2tl6vH9M3 https://t.co/8iuRxoVaJ0

Very nice to meet @KDAO2011 and @uptoTate as the faculty of Rheum Now @RheumNow tune in, follow them and listen to their interviews on the latest updates from #ACR23 https://t.co/I30wdVoqbd

Synovitis in hand #OA genetic risk of synovitis predisposed to clinical and radiographic hand OA @RheumNow #ACR23 https://t.co/aXnXD7UPnv

Rheumatologist - pharmacist co-management of MTX initiators @GeisingerHealth Philadelphia Having the dual skill set actually helped with adherence to guidelines vs standard care. Would be great to see how this works with implementation in RA clinics #ACR23 ABST2484 @RheumNow https://t.co/88R1BYzYn5

#ACR23 Abstr# 2490 Data supporting aggressive early treatment in #SLE? Multicentre open label RCT in China showed low dose MMF + Pred 0.5mg/kg/d reduced severe flare & lupus nephritis cases vs HCQ + Pred in new onset SLE with high dsDNA but w/o major organ involvement @RheumNow https://t.co/oRlgCaOvXo